As a major mediator of cancer-related inflammation, IL-6 is mainly derived from both cancer cells and cancer-associated immune cells, and it has been frequently reported to be increased in the sera, ascites and/or tumor tissue from OC patients correlating with the infiltration of myeloid cells and poor prognosis [29–32]. The gene discussed is IL6; the disease is cancer.